In this case study, Xstrahl 150 was used to treat two patients with Cutaneous Squamous Cell Carcinoma.
Conditions
Contact Us
In this case study, Xstrahl 150 was used to treat two patients with Cutaneous Squamous Cell Carcinoma.
Check out this case study to see the great outcome of a basal cell carcinoma patient thanks to treatment with the RADiant system. See the full case study below.
With the rates of skin cancers ever increasing, especially in places with high sun prevalence, treatment of these conditions can cause not only a demand on resources, but there is a lack of unified response and the best way to treat. This is why Prof. Gerald Fogarty...
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and arises from abnormal growth in the squamous cells of the skin’s outermost layer due to cumulative exposure to ultraviolet radiation. Without treatment, cSCC can be...
Bowen’s disease is a type of squamous cell carcinoma (SCC) in situ of the skin usually characterized by slow-growing, red and scaly patches of skin. Bowen’s disease can be symptomatic and can progress to invasive SCC causing morbidity and even mortality. In their...
The face of skin cancer is changing, as awareness is at an all-time high and medical technology is rapidly advancing. Still, the Skin Cancer Foundation reports that more than 5.4 million cases of nonmelanoma skin cancer are treated each year in the U.S., affecting 3.3...
In the prostate, stem and progenitor cell regenerative capacities have been ascribed to both basal and luminal epithelial cells. Here, we show that a rare subset of mesenchymal cells in the prostate are epithelial-primed Nestin-expressing cells (EPNECs) that can...
OBJECTIVES: Hypoxic cancer cells have been shown to be more resistant to radiation therapy than normoxic cells. Hence, this study investigated whether ultrasound (US)-induced rupture of oxygen-carrying microbubbles (MBs) would enhance the response of breast cancer...
DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between programmed death 1 (PD-1) and its ligand PD-L1 has been...
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |